Advanced oesophageal carcinoma: nivolumab in combination with chemotherapy or ipilimumab prolongs life compared to chemotherapy alone


1 August 2022 - The additional clinical benefit cannot be quantified because the data on health status and health-related quality of life cannot be used.

Nivolumab has recently been approved for the first-line treatment of adults with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma and PD-L1 expression of at least 1%, both in combination with fluoropyrimidine and platinum-based combination chemotherapy and in combination with ipilimumab. 

Read IQWiG press release [German]

Michael Wonder

Posted by:

Michael Wonder